History | Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 147 KB)

Published:

15 June 2023
Register of interests (PDF 154 KB)

Published:

15 June 2023

Final draft guidance

Final draft guidance
Public committee slides (PDF 776 KB)

Published:

11 May 2023
Final appraisal document (PDF 256 KB)

Published:

11 May 2023
Committee papers (PDF 5.3 MB)

Published:

11 May 2023

Invitation to participate

Final scope (PDF 258 KB)

Published:

16 June 2022
Final stakeholder list (PDF 189 KB)

Published:

16 June 2022
Equality impact assessment (Scoping) (PDF 126 KB)

Published:

16 June 2022
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 224 KB)

Published:

16 June 2022

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope post referral (PDF 272 KB)

Published:

25 April 2022
Draft matrix of consultees and commentators post referral (PDF 189 KB)

Published:

25 April 2022